194 related articles for article (PubMed ID: 37240189)
1. The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO).
Tullo MG; Cerulli Irelli E; Caramia F; Tessari G; Di Bonaventura C; Turchetta R; Giallonardo AT; Palumbo G; Bianchi S; Atturo F; Nebbioso M; Mancini P; Guariglia C; Giona F
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240189
[TBL] [Abstract][Full Text] [Related]
2. Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.
Machaczka M; Paucar M; Björkvall CK; Smith NJC; Cox TM; Forsgren L; Svenningsson P
Blood Cells Mol Dis; 2018 Feb; 68():86-92. PubMed ID: 27789132
[TBL] [Abstract][Full Text] [Related]
3. Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients.
Phetthong T; Tim-Aroon T; Khongkraparn A; Noojarern S; Kuptanon C; Wichajarn K; Sathienkijkanchai A; Suphapeetiporn K; Charoenkwan P; Tantiworawit A; Noentong N; Wattanasirichaigoon D
Orphanet J Rare Dis; 2021 Dec; 16(1):519. PubMed ID: 34930372
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1.
Wilke MVMB; Dornelles AD; Schuh AS; Vairo FP; Basgalupp SP; Siebert M; Nalin T; Piltcher OB; Schwartz IVD
Orphanet J Rare Dis; 2019 May; 14(1):103. PubMed ID: 31077260
[TBL] [Abstract][Full Text] [Related]
5. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.
Zhang P; Zheng MF; Cui SY; Zhang W; Gao RP
Endocr Metab Immune Disord Drug Targets; 2022; 22(6):658-662. PubMed ID: 34802413
[TBL] [Abstract][Full Text] [Related]
6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan.
Narita A; Koto Y; Noto S; Okada M; Ono M; Baba T; Sagara R; Sakai N
Orphanet J Rare Dis; 2024 Jan; 19(1):11. PubMed ID: 38183145
[TBL] [Abstract][Full Text] [Related]
8. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients.
Tantawy AAG; Adly AAM; Abdeen MSED; Salah NY
Neurogenetics; 2020 Jul; 21(3):159-167. PubMed ID: 32215803
[TBL] [Abstract][Full Text] [Related]
9. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.
Tantawy AA; Sherif EM; Adly AA; Hassanine S; Awad AH
J Inherit Metab Dis; 2013 Nov; 36(6):1025-37. PubMed ID: 23508695
[TBL] [Abstract][Full Text] [Related]
10. The risk of Parkinson's disease in type 1 Gaucher disease.
Bultron G; Kacena K; Pearson D; Boxer M; Yang R; Sathe S; Pastores G; Mistry PK
J Inherit Metab Dis; 2010 Apr; 33(2):167-73. PubMed ID: 20177787
[TBL] [Abstract][Full Text] [Related]
11. Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.
Furderer ML; Hertz E; Lopez GJ; Sidransky E
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628652
[TBL] [Abstract][Full Text] [Related]
12. Ocular motor abnormalities in Gaucher disease.
Harris CM; Taylor DS; Vellodi A
Neuropediatrics; 1999 Dec; 30(6):289-93. PubMed ID: 10706022
[TBL] [Abstract][Full Text] [Related]
13. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.
Daykin EC; Ryan E; Sidransky E
Mol Genet Metab; 2021 Feb; 132(2):49-58. PubMed ID: 33483255
[TBL] [Abstract][Full Text] [Related]
15. Neurological evaluation of patients with Gaucher disease diagnosed as type 1.
Capablo JL; Saenz de Cabezón A; Fraile J; Alfonso P; Pocovi M; Giraldo P;
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):219-22. PubMed ID: 17682016
[TBL] [Abstract][Full Text] [Related]
16. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.
Baris HN; Cohen IJ; Mistry PK
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1(0 1):72-81. PubMed ID: 25345088
[TBL] [Abstract][Full Text] [Related]
17. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).
Chérin P; Rose C; de Roux-Serratrice C; Tardy D; Dobbelaere D; Grosbois B; Hachulla E; Jaussaud R; Javier RM; Noël E; Clerson P; Hartmann A
J Inherit Metab Dis; 2010 Aug; 33(4):331-8. PubMed ID: 20532983
[TBL] [Abstract][Full Text] [Related]
18. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
[TBL] [Abstract][Full Text] [Related]
19. Polyneuropathy in Gaucher disease type 1 and 3 - a descriptive case series.
Andréasson M; Solders G; Björkvall CK; Machaczka M; Svenningsson P
Sci Rep; 2019 Oct; 9(1):15358. PubMed ID: 31653957
[TBL] [Abstract][Full Text] [Related]
20. Are There Neurological Symptoms in Type 1 of Gaucher Disease?
Alaei M; Jafari N; Rohani F; Ahmadabadi F; Azadi R
Iran J Child Neurol; 2018; 12(2):99-106. PubMed ID: 29696051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
